Abstract:956 Background: Most patients with metastatic cancer will eventually succumb to their disease despite an initial response to chemotherapy. To enhance treatment efficacy, chemotherapy has been combined with cytokines, often with disappointing results. Another example is “Immunocentric Chemoimmunotherapy,” with primary focus placed on immunotherapy, with chemotherapy as an immunomodulator. We have developed a novel strategy termed “Chemocentric Chemoimmunotherapy,” where chemotherapy plays the central role, with immunotherapy as a chemosensitizer. The rationale is the ability of activated T cells to secret multiple cytokines, which may regulate gene expression in tumor cells. Methods: Human CD4+ T cells were isolated and activated with anti-CD3/anti-CD28 mAb. Tumor cells were presensitized with activated CD4+ T cells (aCD4), followed by treatment with various chemotherapy. Cell viability and apoptosis were determined. Transwell system was used to assess contribution of cell-cell contact vs. soluble factor(s). Results: Presensitization of A375 melanoma cells with aCD4 synergistically enhanced the cytotoxic effects of chemotherapy. Cell viability (CV) was 75% (+SD: 0.11) and 90% (+SD: 0.26) after treatment with temozolomide (TMZ) alone or with aCD4 alone, respectively. However, CV in the experimental group was 7% (+SD: 0.02). This synergistic effect was also observed with other melanoma cell lines, nonmelanoma tumor cell lines, and other chemotherapy. Two breast, one prostate, and one colon cancer cell lines were presensitized with aCD4, followed by treatment with paclitaxel, carboplatin, or 5-FU. Consistent synergistic effect was seen in each case. For example, CV in MDA-MB-231 breast cancer cells treated with paclitaxel alone or aCD4 alone was 93% (+SD: 0.16) and 52% (+SD: 0.10), respectively. However, CV in the experimental group was 8% (+SD: 0.18). The same synergism was observed in DU145 prostate cancer cell line treated with carboplatin. CV in the carboplatin-treated group and aCD4-treated group was 100% (+ SD: 0.13) and 75% (+SD: 0.14), respectively; while CV of the experimental group was 5% (+SD: 0.19). The rate of apoptosis in cells treated with both TMZ and aCD4 was 20 times higher than in cells treated with only TMZ or aCD4. This effect was due entirely to soluble factors. The aCD4 was found to secret large amounts of multiple cytokines. Preliminary data showed that IFN-γ might not be the major cytokine mediating the observed effect. Conclusion: Presensitization of tumor cells with aCD4 synergistically enhanced the cytotoxic effect of chemotherapy. This effect was completely dependent on soluble factors, most likely cytokines. We are in the process of elucidating the mechanisms underlying this dramatic synergy.

A Combination Therapy of Cyclophosphamide and Immunomodulating Agents in Cancer

Mechanisms involved in synergistic anticancer effects of anti-4-1BB and cyclophosphamide therapy

"Cyclophosphamide and analogues; a matter of dose and schedule for dual anticancer activities"

Definitive activation of endogenous antitumor immunity by repetitive cycles of cyclophosphamide with interspersed Toll-like receptor agonists

The Intestinal Microbiota Modulates the Anticancer Immune Effects of Cyclophosphamide

Cyclophosphamide augments the efficacy of in situ vaccination in a mouse melanoma model

Immunological aspects of cancer chemotherapy

Cyclophosphamide enhances anti-tumor effects of a fibroblast activation protein α-based DNA vaccine in tumor-bearing mice with murine breast carcinoma.

Combinatorial Approach to Improve Cancer Immunotherapy: Rational Drug Design Strategy to Simultaneously Hit Multiple Targets to Kill Tumor Cells and to Activate the Immune System

Immunoregulatory cyclophilin a improves low-dose chemotherapy with a modulation of the immune tumor microenvironment in experimental models of melanoma B16 and lymphoma EL4 in vivo

Significantly Positive Impact of Nonsteroidal Anti-inflammatory Drugs Combined With Osmoprotectant (Osmolytes) in Cancer Treatment

Tretinoin improves the anti-cancer response to cyclophosphamide, in a model-selective manner

"Chemocentric" Chemoimmunotherapy: Presensitization of Tumor Cells with Activated Cd4+T Cells Synergistically Enhances the Cytotoxic Effect of Chemotherapy

Increase of CD4+CD25+ regulatory T cells in the peripheral blood of patients with metastatic carcinoma: a Phase I clinical trial using cyclophosphamide and immunotherapy to eliminate CD4+CD25+ T lymphocytes

Low-dose cyclophosphamide combined with IL-2 inhibits tumor growth by decreasing regulatory T cells and increasing CD8+ T cells and natural killer cells in mice

Tumor-Targeting Salmonella Typhimurium Improves Cyclophosphamide Chemotherapy At Maximum Tolerated Dose And Low-Dose Metronomic Regimens In A Murine Melanoma Model

Combining chemotherapy with CAR-T cell therapy in treating solid tumors

Role of synergy and immunostimulation in design of chemotherapy combinations: An analysis of doxorubicin and camptothecin

Single administration of low dose cyclophosphamide augments the antitumor effect of dendritic cell vaccine

Combination of radiotherapy and immunotherapy in duality with the protumoral action of radiation

Combinatorial regimens of chemotherapeutic agents: A new perspective on raising the heat of the tumor immune microenvironment